The first BH3-mimetic with high anti-tumor activity was the dual BCL-2/BCL-XL inhibitor ABT-737 [16], whose diminished efficacy observed in MM cells when co-cultured with BM-MSCs was partially reverted by IL6 blockage [17]. This evidence concerns the gene BCL2 and Miyoshi myopathy.